Two-year adverse events in patients allocated to tirofiban + sirolimus-eluting stent (tirofiban + sirolimus-eluting stent [SES] group) and in patients randomized to abciximab infusion plus bare-metal stenting (abciximab + bare-metal stent [BMS] group). Cumulative risk of major adverse events (A), death or myocardial infarction (B), and target vessel revascularization (C).

Cumulative risk of death or nonfatal myocardial infarction after thienopyridine discontinuation in patients either allocated to receive tirofiban + SES or abciximab + BMS. (1) Patient #115 experienced a sudden death at home 8 days after ticlopidine discontinuation. (2) Patient #105 presented 8 days after clopidogrel discontinuation at emergency department with typical chest pain, cardiogenic shock, and new-onset left bundle branch block. The patient died immediately after admission, before a diagnostic coronary angiogram could be obtained. (3) Patient #15 died suddenly at home 22 days after clopidogrel discontinuation. (4) Patient #165 died 23 days after ticlopidine discontinuation from gastric cancer. (5) Patient #42 had a reinfarction 28 days after clopidogrel discontinuation due to an angiographically confirmed disease progression in the first obtuse marginal branch (the patient underwent intervention in the left anterior descending artery at the time of index event). (6) Patient #45 was a 78-year-old male with a history of anterior infarction who was treated at the time of the index procedure for a proximal occlusion of a dominant circumflex artery who died due to end-stage heart failure 24 days after ticlopidine discontinuation. (7) Patient #94 died 18 days after clopidogrel discontinuation due to chronic obstructive pulmonary disease. (8) Patient #54 experienced non–Q-wave lateral myocardial infarction 15 days after clopidogrel discontinuation. The patient received treatment at the circumflex artery at the time of the index procedure and refused recatheterization. Abbreviations as in Figure 1.